Bill has been an Independent Director for Nulcera Bio since January 2025 and has served as CFO for Telesis Bio since August 2023. He has over 30 years of experience as a CFO in a broad range of financial management and operational roles, primarily in mid-sized to large corporations, including multiple publicly held life-science companies. Prior to joining Telesis Bio, Bill served for over five years as CFO of BioLegend, Inc., a worldwide provider of life science antibodies and reagents, where he led the company’s September 2021 sale to NYSE-listed Revvity for $5.25 billion, the largest acquisition in Revvity’s history. Before joining BioLegend in 2017, Bill served as CFO of Lombard Medical, Inc. (Nasdaq: EVAR) from 2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation. Similar prior CFO appointments at other life science and technology companies have resulted in a host of successful transactions involving debt, M&A, and public offerings. Bill earned both his MBA and bachelor’s degree from the State University of New York at Buffalo.